Discontinued — last reported Q4 '20
Viatris Business Sale Proceeds decreased by 36.0% to $1.60M in Q1 2026 compared to the prior quarter. Over 4 years (FY 2021 to FY 2025), Business Sale Proceeds shows a downward trend with a -59.9% CAGR.
An increase signals portfolio optimization or a strategic pivot, while a lack of proceeds suggests a stable, long-term asset base.
This metric represents the cash inflows received from the divestiture or sale of business segments, product lines, or su...
Occurs sporadically; peers often divest legacy segments to focus on high-margin innovation areas like continuous glucose monitoring or diagnostics.
proceeds_from_sale_of_business| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $70.90M | $13.10M | $200.00K | $5.10M | -$5.10M | $0.00 | $1.95B | $0.00 | $0.00 | $48.00M | $316.10M | $240.60M | $437.10M | $1.83B | $0.00 | $0.00 | $0.00 | $0.00 | $2.50M | $1.60M |
| QoQ Change | — | -81.5% | -98.5% | >999% | -200.0% | +100.0% | — | -100.0% | — | — | +558.5% | -23.9% | +81.7% | +319.2% | -100.0% | — | — | — | — | -36.0% |
| YoY Change | — | — | — | — | -107.2% | -100.0% | >999% | -100.0% | +100.0% | — | -83.8% | — | — | >999% | -100.0% | -100.0% | -100.0% | -100.0% | — | — |